Fig. 1: Study design and consort diagram.
From: Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
a Study design diagram. AC Adriamycin (Doxorubicin) + Cyclophosphamide, T Taxol (Docetaxel), H Herceptin (Trastuzumab), NAC neoadjuvant chemotherapy, pCR pathologic complete response. (b) Consort diagram for patient enrollment, sample collection and data generation. Tissues were not collected for nine patients who withdrew consent. *55 patients were excluded from NGS data generation due to tissue collection failure (33), follow-up failure (7), withdrawal of consent (6), non-breast cancer pathology (4), distant progression and exclusion from surgery (3), NAC termination (1) and expiration (1). Two non-pCR patients had paired T1, T3 samples. WTS whole transcriptome sequencing.
